Reduced-intensity stem cell transplantation in children and adolescents:: The Mexican experience

被引:53
作者
Gómez-Almaguer, D
Ruiz-Argüelles, GJ
Tarín-Arzaga, LD
González-Llano, O
Jaime-Pérez, JC
López-Martínez, B
Cantú-Rodríguez, OG
Herrera-Garza, JL
机构
[1] Ctr Hematol & Med Interna Puebla, Puebla 72530, Mexico
[2] Univ Autonoma Nuevo Leon, Univ Hosp, Monterrey, Nuevo Leon, Mexico
[3] Lab Clin Puebla, Puebla, Mexico
关键词
children; allograft; nonmyeloablative; transplant;
D O I
10.1016/S1083-8791(03)70004-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A group of 21 consecutive patients aged 4-20 (median 13) years was prospectively allografted using a reduced intensity preparative regimen. The group included both malignant (acute lymphoblastic leukemia, acute myelogenous leukemia, and chronic myelogenous leukemia) and nonmalignant (aplastic anemia, Diamond-Blackfan anemia, thalassemia major and adrenoleukodystrophy) conditions. Follow-up times ranged between 16 and 1038 days. Four of 21 patients (9.5%) developed acute graft-versus-host disease, and 2 of them died, whereas limited chronic graft-versus-host disease was observed in 2 of 15 cases. The 100-day mortality was 19%. Median overall survival was above 1038 days, whereas the 34-month survival was 55%. These data show that reduced intensity stem cell transplantation in children permits rapid engraftment from siblings with little toxicity. (C) 2003 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:157 / 161
页数:5
相关论文
共 21 条
  • [1] Non-myeloablative stem cell transplants
    Barrett, J
    Childs, R
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (01) : 6 - 17
  • [2] REGIMEN-RELATED TOXICITY IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION
    BEARMAN, SI
    APPELBAUM, FR
    BUCKNER, CD
    PETERSEN, FB
    FISHER, LD
    CLIFT, RA
    THOMAS, ED
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) : 1562 - 1568
  • [3] Childs R, 1999, BLOOD, V94, p393A
  • [4] Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
    Giralt, S
    Estey, E
    Albitar, M
    vanBesien, K
    Rondon, G
    Anderlini, P
    OBrien, S
    Khouri, I
    Gajewski, J
    Mehra, R
    Claxton, D
    Andersson, B
    Beran, M
    Przepiorka, D
    Koller, C
    Kornblau, S
    Korbling, M
    Keating, M
    Kantarjian, H
    Champlin, R
    [J]. BLOOD, 1997, 89 (12) : 4531 - 4536
  • [5] Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis:: report of four cases
    Gómez-Almaguer, D
    Ruiz-Argüelles, GJ
    Ruiz-Argüelles, A
    González-Llano, O
    Cantú, OE
    Hernández, NE
    [J]. BONE MARROW TRANSPLANTATION, 2000, 25 (02) : 131 - 133
  • [6] Transplant-lite:: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies
    Khouri, IF
    Keating, M
    Körbling, M
    Przepiorka, D
    Anderlini, P
    O'Brien, S
    Giralt, S
    Ippoliti, C
    von Wolff, B
    Gajewski, J
    Donato, M
    Claxton, D
    Ueno, N
    Andersson, B
    Gee, A
    Champlin, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2817 - 2824
  • [7] MCGLAVE PB, 1988, BLOOD, V72, P1512
  • [8] Miniero Roberto, 2000, Haematologica, V85, P12
  • [9] Pession A, 2000, HAEMATOLOGICA, V85, P638
  • [10] Ruiz Arguelles G J, 2000, Haematologica, V85, P1233